Stockwinners Market Radar for February 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EST Cathie Wood's ARK Investment bought 130K shares of Roblox today

19:11 EST Global System Dynamics sponsor DarkPulse requested extension to complete merger - Global System Dynamics "announced that its sponsor, DarkPulse, has requested a one-month extension to complete its initial business combination. Per the terms of the agreement, the Sponsor will deposit an aggregate of $83,947.13 into the Company's trust account for the benefit of its valued public stockholders. This additional contribution enables the Company to extend the date by which the Company has to complete its initial business combination for an additional one-month extension from February 9, 2023 to March 9, 2023. Such contribution effectively increases the pro rata portion of the funds available in the Company's trust account in the event of the consummation of an initial business combination, liquidation, or other redemption event, by $0.0625 per share. The request is subject to approval by the Company's Board of Directors. Should the Company's Board of Directors approve the Sponsor's request, the Sponsor has until February 9, 2023 to deposit the funds into the Company's trust account. The Sponsor's contribution will be funded as a non-interest bearing loan that will either be paid upon earlier of consummation of an initial business combination or the company's liquidation, or, at the lender's discretion and subject to certain conditions, converted upon consummation of the initial business combination into additional units, at a price of $10.00 per unit, identical to the units issued in the Company's private placement that was consummated in connection with the Company's initial public offering."

18:47 EST Momentus provides Vigoride-5 status update - Momentus announced that its Vigoride-5 Orbital Service Vehicle launched on the SpaceX Transporter-6 mission on January 3 continues to be in good health and that the team is continuing to fully commission the vehicle in preparation for further on-orbit operations. Recent activities have focused on tuning the performance of the attitude determination system and beginning pressurization of the vehicle's propulsion system. The vehicle's power and temperatures continue to be within the nominal expected ranges.

18:26 EST Stryker CFO Boehnlein sells $6.8M in common stock - In a regulatory filing, Stryker disclosed that its CFO Glenn Boehnlein had sold 24.4K shares of its common stock during February 2nd in a total transaction size of $6.8M.

18:04 EST SoFi Technologies general counsel Lavet sells 200,000 common shares - In a regulatory filing, SoFi Technologies general counsel Robert Lavet disclosed the sale of 200,000 common shares of the company on February 2 at a price of $8.062 per share.

17:59 EST Aesther Healthcare acquisition jumps 18% after approval for combination - SPAC Aesther Healthcare and Ocean Biomedical announced that its stockholders approved all proposals related to the previously announced proposed business combination between Aesther and Ocean at a special meeting of stockholders held on February 3, 2023.

17:51 EST USD Partners amends existing revolving credit facility - On January 31 USD Partners and USD Terminals Canada an indirect, wholly-owned subsidiary of the Partnership and the subsidiary guarantors party thereto, entered into an amendment to the Borrowers' existing revolving credit agreement, dated as of November 2, 2018. Among other things, the Amendment provides the Partnership with relief from compliance with the Credit Agreement's maximum consolidated leverage ratio and minimum consolidated interest coverage ratio through the Credit Agreement's current maturity date, as management works to obtain renewals, extensions or replacements of agreements that expired during 2022 and those that are set to expire this year. Management continues to see positive momentum around the Partnership's re-contracting negotiations. Additional details regarding the Amendment are included in the Partnership's Current Report on Form 8-K filed on February 6.

17:46 EST Univar acquires ChemSol Group fro undisclosed amount - Univar Solutions announced that it has acquired ChemSol Group, a leading ingredients and specialty chemicals distributor operating in Costa Rica, Guatemala, El Salvador, Panama, and Honduras. Univar Solutions to Expand Central American Presence with ChemSol AcquisitionThe acquisition of ChemSol will enhance the Company's geographic footprint in the growing Central American region, as well as its formulation and commercial offering across a wide array of key growth markets. These markets include beauty and personal care; pharmaceutical excipients; food; coatings, adhesives, sealants, and elastomers; lubricants and metalworking fluids. Terms of the transaction were not disclosed.

17:41 EST Comcast reduces stake in BuzzFeed to 15.9% from 20.0% - In a regulatory 13D/A filing, BuzzFeed (BZFD) disclosed that the Comcast (CMCSA) stake in the company has been reduced to 15.9% from 20.0% reported on February 1st. Shares of BuzzFeed are down 2.7% afterhours at $2.14.

17:27 EST Bed Bath & Beyond continues drop, now down 26% after announcing stock offering

17:26 EST Starboard Value reports 6.5% stake in Rogers Corporation - Starboard Value disclosed it holds a 6.5% stake in Rogers Corporation, or 1.22M shares. Starboard purchased the shares based on its belief that the shares, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to Starboard, and the availability of shares at prices that would make the purchase or sale of shares desirable,Starboard may endeavor to increase or decrease their position in Rogers through, among other things, the purchase or sale of shares on the open market or in private transactions or otherwise, on such terms and at such times as it may deem advisable.

17:17 EST InterDigital raises price range for $200M buyback tender offer - InterDigital announced that it is amending its previously announced modified "Dutch auction" tender offer to purchase for cash up to $200M of its common stock. The Tender Offer was originally set at a price per share not less than $60.00 and not greater than $69.00, less any applicable withholding taxes and without interest. As amended, the Tender Offer is now set at a price per share not less than $65.25 and not greater than $75.00, less any applicable withholding taxes and without interest. On February 3, 2023, the last full trading day before the amendment of the Tender Offer, the closing price of the Common Stock was $71.29 per share. The Tender Offer will expire at 11:59 p.m., New York City time, on February 17, 2023, unless extended or terminated.

16:56 EST Bed Bath & Beyond falls 13% after announcing stock offering

16:33 EST WhiteHorse Finance increases capital commitments to joint venture - WhiteHorse Finance announced that the Company, together with State Teachers Retirement System of Ohio, a public pension fund established under Ohio law, or STRS Ohio, have increased their capital commitments to their joint venture, WHF STRS Ohio Senior Loan Fund by $25M. The increased commitment will be funded by an incremental $15M investment from WhiteHorse Finance and an incremental $10M investment from STRS Ohio bringing total capital commitments to the WHF STRS JV to $175M. The WHF STRS JV was established in 2019 to invest primarily in lower middle market senior secured debt facilities.

16:31 EST Carrier Global strengthens climate goals - Carrier Global announced plans to reduce its greenhouse gas emissions in line with the Science Based Targets initiative to limit global warming to 1.5 C. These new goals, including a net zero target, will build on Carrier's previous, ambitious 2030 Environmental, Social & Governance goals, and further support decarbonization efforts. Carrier is now targeting net-zero GHG emissions across its value chain by 2050, complementing its existing goal of helping its customers avoid more than 1 gigaton of GHG emissions by 2030. The company's comprehensive sustainability strategy addresses scope 1, 2 and 3 emissions, covering enterprise-wide direct and indirect emissions. Near- and long-term goals addressing Carrier's scope 1, 2, and 3 emissions will be developed and published in accordance with the SBTi validation process.

16:26 EST T2 Biosystems advances in HHS and Cohen Foundation's LymeX Diagnostics Prize - T2 Biosystems announced that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services and the Steven & Alexandra Cohen Foundation's LymeX Diagnostics Prize. The goal of the multiphase LymeX Innovation Accelerator prize competition is to nurture the development of diagnostics toward Food and Drug Administration review. "We are thrilled to announce that we have advanced to the Phase 2 accelerator in the LymeX Diagnostics Prize," stated John Sperzel, Chairman and CEO of T2Biosystems. "We appreciate the leadership from HHS and the Cohen Foundation to advance next generation Lyme diagnostics, and we are grateful to receive this support to advance our T2Lyme Panel for the detection of early Lyme disease."The LymeX Diagnostics Prize Virtual Accelerator provides a pathway to nurture the development of the next generation of Lyme disease diagnostics toward FDA submission and market. ..

16:23 EST MSG Entertainment exploring potential sale of Tao Group interest - Madison Square Garden Entertainment Corp. announced the company is exploring a potential sale of its majority interest in Tao Group Hospitality. Since MSG Entertainment acquired its interest in 2017, Tao Group Hospitality has transformed into a global entertainment dining and nightlife powerhouse, with more than 70 branded locations in over 20 markets across four continents. MSG Entertainment regularly evaluates ways to maximize shareholder value and believes that now is the appropriate time to explore a potential sale of its interest in Tao Group Hospitality. There is no assurance this exploration process will result in a transaction.

16:22 EST Kernel announces charter & trust amendments, intends extension for combination - Kernel Group Holdings announced that its shareholders approved amendments to its charter and trust agreement to change the structure and cost of how KRNL can obtain extensions to the deadline to complete its initial business combination and that KRNL obtained the first of up to six 1-month extensions of the deadline - from February 5, to March 5 - by depositing $300,000 into its trust account with Continental Stock Transfer and Trust Company . KRNL's shareholders, at an extraordinary general meeting of its shareholders held on February 3, 2023, approved amendments to KRNL's Amended and Restated Articles of Association and KRNL's Investment Management Trust Agreement dated February 5, 2021 with Continental to change how KRNL can obtain extensions to the previously applicable February 5, deadline to complete its initial business combination. The amendments allow KRNL to instead obtain up to six 1-month extensions by depositing the lesser of (x) $300,000 or (y) 6c per outstanding public share into the Trust Account by the deadline applicable prior to the extension.The Charter Amendment triggered a right of KRNL's public shareholders to demand the redemption of their public shares out of funds held in the Trust Account. Holders of 22,848,122 public shares properly requested redemption leaving 7,626,878 public shares outstanding. After payment of the redemption price to the redeeming public shareholders of approximately $10.15 per share for an aggregate of $231.9 million, KRNL will have approximately $74.7 million left in its Trust Account. Based on the shares redeemed, the $300,000 per month represents approximately $0.04 per unredeemed share.

16:21 EST NOG says severe weather affected Williston, Permian volumes in Q4 - Northern Oil and Gas said that during the fourth quarter of 2022, severe weather affected production volumes in the Williston and Permian Basins. The Company estimates that its December production was impacted by approximately 10,000 Boe per day, with the Williston Basin accounting for approximately 82% of the reduction and the Permian representing approximately 18%. Despite weather related outages, the Company expects total 2022 production in the range of 75,250 to 75,550 Boe per day, in line with prior guidance. NOG expects total production volumes to be slightly lower for the fourth quarter of 2022 compared to the third quarter, but with higher average daily oil production than in the third quarter of 2022. Total acquisition and development capital expenditures are expected to be in the range of $143-145 million for the fourth quarter. Despite the severe weather, the Company turned-in-line 19.9 net wells during the fourth quarter, with 5.9 net wells in late December, building strong momentum into 2023. Operations have substantially returned to normal in January 2023.

16:20 EST Leggett & Platt sees FY23 CapEx $100M - Sees FY23: Operating cash flow $450M-$500M; Dividends $240M; Effective tax rate 24%; Minimal acquisitions and share repurchases.

16:17 EST Holley names Michelle Gloeckler interim CEO - Holley "announced that Tom Tomlinson will retire as President and CEO and resign from the Board. The Board has appointed current Director, Michelle Gloeckler, as Interim President and CEO while it conducts a comprehensive search process to identify a permanent CEO. The search will be conducted with the assistance of Heidrick & Struggles, who was retained by the Board in September 2022 for a comprehensive review of succession planning. Ms. Gloeckler has been a member of the Board since July 2021 and has over 30 years of experience in consumer-packaged goods, merchandising, sourcing, manufacturing and strategy."

16:15 EST OceanTech Acquisitions I confirms funding extending business combination period - OceanTech Acquisitions I announced that on February 2, 2023 it caused to be deposited $125,000 into the Company's Trust account for its public stockholders, representing $0.067 per public share, allowing the Company to extend the period of time it has to consummate its initial business combination by one month from February 2, 2023 to March 2, 2023. The Extension is the third of six-monthly extensions permitted under the Company's governing documents.

16:13 EST Spirit Airlines sees Q1 ASM up 13.2%

16:12 EST Genworth names Jerome Upton as CFO - Genworth Financial "announced an update to its senior leadership structure whereby it will separate the roles of Chief Financial Officer and Chief Investment Officer in early March. At that time, Dan Sheehan will transition out of his current combined role of Executive Vice President, CFO and CIO. Jerome Upton will be appointed Executive Vice President and CFO, and Kelly Saltzgaber will be appointed Executive Vice President and CIO. Sheehan will remain in his current combined role through the completion of the company's fourth quarter financial close process and related Form 10-K filing, which is expected to occur in late February. He will then remain with the company in an advisory role until March 31, 2023 in order to ensure a smooth transition."

16:10 EST Pinterest sees Q1 revenue up low single digits - The company states: "Our current expectation is that Q1 2023 revenue will grow low single digits on a year-over-year percentage basis, which takes into account slightly lower foreign exchange headwinds than Q4 2022. We expect our Q1 2023 non-GAAP operating expenses to decline to low double digits percent quarter-over-quarter."

16:08 EST Pinterest CFO Todd Morgenfeld to step down - Pinterest announced that Todd Morgenfeld, Chief Financial Officer and Head of Business Operations, will transition from Pinterest to pursue new career opportunities on July 1, 2023. As part of this announcement, effective immediately, Andrea Mallard, Chief Marketing and Communications Officer and Bill Watkins, Chief Revenue Officer, will now report directly to Bill Ready, CEO. These functions are critical to delivering value to Pinners and advertisers and will work closely with the Executive Team on executing against strategic priorities.

16:06 EST PetMed Express announces quarterly dividend of 30c per share - The Board of Directors declared a quarterly dividend of 30c per share on the Company's common stock. The dividend will be payable on February 27, to shareholders of record at the close of business on February 20, . The declaration and payment of future dividends is discretionary and will be subject to the determination by the Board of Directors. Based on a sales tax assessment received and accrued in the second quarter fiscal year 2023, the Company initiated a process to evaluate the potential for further sales tax contingencies, We expect to complete the evaluation in the quarter ending March 31, 2023, the results of which could have a material effect on the results of operations.

16:02 EST Bit Digital reports bitcoins January production up 3% - Bit Digital announced its unaudited bitcoin production and corporate updates for the month of January. Corporate Highlights for January 2023 include: In January the Company earned 134.3 bitcoins, a 3% increase compared to the prior month. The increase in production was primarily driven by a higher average active hash rate, partially offset by an increase in network difficulty. Treasury holdings of BTC and ETH were 970.6 and 10,222.3 with a fair market value of approximately $22.5M and $16.2M, respectively, on January 31. The BTC equivalent of our digital asset holdings as of January 31 was approximately 1,855.7, or approximately $42.9M. The Company had cash and cash equivalents of $28.0M as of January 31. The Company did not purchase or sell any miners during the month.

15:33 EST AMC Entertainment trading resumes

14:54 EST Independent Bank raises quarterly cash dividend 5% to 23c per share - Independent Bank Corporation, the holding company of Independent Bank, a Michigan-based community bank, announced that its board of directors declared a quarterly cash dividend on its common stock of 23c per share. This dividend is payable on February 24 to shareholders of record on February 16. The quarterly dividend represents a 5% increase over the quarterly dividend rate paid for each quarter in 2022.

14:04 EST Google releases conversational AI service Bard for testing - Google said in a blog post, "We've been working on an experimental conversational AI service, powered by LaMDA, that we're calling Bard. And today, we're taking another step forward by opening it up to trusted testers ahead of making it more widely available to the public in the coming weeks. Bard seeks to combine the breadth of the world's knowledge with the power, intelligence and creativity of our large language models. It draws on information from the web to provide fresh, high-quality responses. Bard can be an outlet for creativity, and a launchpad for curiosity, helping you to explain new discoveries from NASA's James Webb Space Telescope to a 9-year-old, or learn more about the best strikers in football right now, and then get drills to build your skills. We're releasing it initially with our lightweight model version of LaMDA. This much smaller model requires significantly less computing power, enabling us to scale to more users, allowing for more feedback. We'll combine external feedback with our own internal testing to make sure Bard's responses meet a high bar for quality, safety and groundedness in real-world information. We're excited for this phase of testing to help us continue to learn and improve Bard's quality and speed." Reference Link

13:42 EST Reed asked FTC to crack down on possible egg price gouging - Previously, in a letter dated January 24, Senator Jack Reed asked the Federal Trade Commission, or FTC, and Chair Lina Khan to look into the high prices of eggs and possible price gouging by big egg companies. In his announcement of the letter asking for the probe, Reed noted that "the largest U.S. egg producer," Cal-Maine Foods, which the Senator said "controls 20 percent of the retail egg market" reported "record profits of $323 million as of the most recent quarter, swinging from a loss of $16.8 million during the same period in the previous year." Reference Link

13:35 EST VinFast Auto says U.S. Bank chosen as preferred financing provider in U.S. - VinFast (VFS) announced U.S. Bank (USB) has been chosen as its preferred provider of retail financing and leasing of VinFast vehicles in the United States. Under the partnership, U.S. Bank will officially provide financing and leasing solutions for VinFast vehicles at VinFast showrooms and via the VinFast website. The announcement comes as VinFast is preparing to open more showrooms in California, with plans for more locations around the country soon, the company said. "With the goal to make electric vehicles accessible to everyone, VinFast is constantly looking for optimal solutions for customers. Thanks to this agreement, VinFast customers will have access to competitive finance and lease rates and world-class customer service from U.S. Bank," said Madam Le Thi Thu Thuy, Vingroup Vice Chair and CEO of VinFast Holdings. Previously, in December 2022, VinFast Auto announced it had filed for an initial public offering of it ordinary shares and intended to apply to list its ordinary shares on the Nasdaq Global Select Market under the symbol "VFS."

13:00 EST BMO U.S. raises minimum hourly wage to $20 per hour - BMO announced it will raise its minimum hourly wage for all qualified U.S. employees to $20 per hour effective March 12, 2023, as part of the bank's ongoing commitment to the financial wellbeing and progress of its employees. The increase applies to new hires and current team members from BMO U.S. and the recently acquired Bank of the West who earn below the new minimum base pay. "BMO has one of the best teams in banking and we want to reward our team in a way that reinforces their value to our organization and is competitive with the market," said Larissa Chaikowsky, U.S. Chief Human Resources Officer and Head, Talent Reskilling & Acceleration, BMO. "Our colleagues are critical to BMO's success, and we continue to be committed to making investments in our people to ensure they can make real financial progress alongside our customers and our communities."

12:07 EST Kroger to expand Gotham Greens to over 1,000 stores - The Kroger Co. and Gotham Greens are bringing greenhouse-grown produce and fresh, plant-based foods to more customers across the country. Kroger customers can find Gotham Greens' produce in more than 300 stores today, with plans to expand to nearly 1,000 stores by the end of 2023, helping bring Kroger's commitment to fresh food for everyone to life. In addition to produce, the expansion of Gotham Greens' plant-based dips, cooking sauces and dressings will put the supplier in nearly 2,000 Kroger locations across the country.

12:03 EST FirstService increases quarterly cash dividend 11% to 22.5c per share - FirstService Corporation announced that its board of directors has approved an 11% increase in the quarterly cash dividend on the outstanding common shares of the company over the previous 20.25c per common share and declared a quarterly dividend of 22.5c per common share. The dividend is payable on April 11 to holders of common shares of record at the close of business on March 31. The company's dividend will be 90c on an annualized basis, up from 81c during the past year.

12:00 EST Gaotu Techedu falls -10.5% - Gaotu Techedu is down -10.5%, or -39c to $3.31.

12:00 EST BigBear.ai rises 10.6% - BigBear.ai is up 10.6%, or 55c to $5.74.

12:00 EST Catalent rises 20.2% - Catalent is up 20.2%, or $11.34 to $67.39.

11:01 EST HII wins $25M DLA contract to streamline technologies for U.S. warfighters - HII announced that its Mission Technologies division has been awarded a $21M recompete contract by the Defense Logistics Agency to research and develop technical solutions that will streamline the delivery of products and materials to the warfighter and support DLA's global mission. The objective of the contract task order is to research, develop and recommend innovative solutions for defense system logistics services, supply chains, materials and products managed by the DLA in order to maximize operational efficiency and effectiveness. "We are pleased to expand our partnership with DLA to help address supply chain interruptions and manufacturing challenges that have become a national priority," said Grant Hagen, president of HII's Mission Technologies Cyber, Electronic Warfare & Space business group.

10:37 EST ServiceNow slips after CEO McDermott sells about $25M in shares - In a regulatory filing after the close on Friday, it was disclosed that ServiceNow Chairman and CEO Bill McDermott sold 53,933 shares of the company's common stock on Feb. 1 at prices ranging from $454.55-$461.07 per share in transactions with a total aggregate value of about $24.75M. In early Monday trading, shares of ServiceNow are down $13.19, or about 3%, to $459.03. Reference Link

10:04 EST Albertsons launches Sincerely Health platform - Albertsons Companies announced the launch of Sincerely Health, a digital health and wellness platform that is now accessible on 16 of its banners' grocery app and websites including Albertsons, Safeway, Vons, Shaw's, Jewel-Osco, Acme, Tom Thumb and more. The company said, "Backed by science, Sincerely Health is designed to help improve lives by connecting, educating, encouraging and rewarding customers on their health and wellness journey so they can make informed choices regarding food, physical activity, sleep and mindfulness. Sincerely Health is a platform built in collaboration with healthcare providers, insurance companies and technology organizations who share a broader purpose to improve the health and well-being of every community they serve. The teams also gleaned valuable insights gathered from over 10,000 customers and associates. The platform will continually evolve based on customer feedback, which will also inform new features, collaborations and enhancements to position Sincerely Health as a trusted and reliable health resource."

10:00 EST Gaotu Techedu falls -9.2% - Gaotu Techedu is down -9.2%, or -34c to $3.36.

10:00 EST Bright Scholar falls -10.6% - Bright Scholar is down -10.6%, or -36c to $3.04.

10:00 EST BigBear.ai rises 15.0% - BigBear.ai is up 15.0%, or 78c to $5.97.

09:52 EST Arrow Financial names Penko Ivanov as CFO - Arrow Financial is pleased to announce the appointment of Penko Ivanov, CPA, MBA, as CFO, Executive Vice President, Treasurer and Chief Accounting Officer of Arrow and its two subsidiary banks, Glens Falls National Bank and Trust Company and Saratoga National Bank and Trust Company, as well as its insurance subsidiary, Upstate Agency, LLC., effective February 21. Ivanov most recently served as Executive Vice President and CFO of Bankwell Financial Group in New Canaan, Connecticut.

09:47 EST Bright Scholar falls -11.2% - Bright Scholar is down -11.2%, or -38c to $3.02.

09:47 EST Graham rises 10.4% - Graham is up 10.4%, or $1.13 to $12.00.

09:47 EST Catalent rises 23.7% - Catalent is up 23.7%, or $13.29 to $69.34.

09:37 EST Tyson Foods: Retail chicken softer than expected in November, December

09:35 EST Tyson Foods sees Q2 'seasonally softer' than Q1 - Comments taken from Q1 earnings conference call.

09:30 EST OceanPal announces time charter contract for m/v Baltimore - OceanPal announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for its Capesize dry bulk vessel, the m/v Baltimore. The gross charter rate is US$13,300 per day minus a 5% commission paid to third parties, for a period of minimum five months to about eight months. The charter is expected to commence on February 9, 2023. The m/v Baltimore is currently chartered to Enesel Bulk Logistics DMCC at a gross charter rate of US$12,900 per day, minus a 5% commission paid to third parties. The "Baltimore" is a 177,243 dwt Capesize dry bulk vessel built in 2005. The employment of "Baltimore" is anticipated to generate approximately US$2.0 million of gross revenue for the scheduled period of the time charter.

09:18 EST Alset prices $3.8M underwritten public offering of common stock - Alset announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be $3.8M, before deducting underwriting discounts and other estimated expenses payable by the Company. The offering consists of 1,727,273 shares of common stock at a price of $2.20 per share. In addition, the Company has granted Aegis Capital Corp., the underwriter in the offering, a 45-day option to purchase up to an additional 212,863 shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from this offering for general working capital. The closing of the Offering is expected to occur on February 8, 2023, subject to customary closing conditions. Aegis Capital Corp. is acting as the sole book-running manager for the offering.

09:14 EST NeuroSense announces Canada approved patient enrollment for PARADIGM study - NeuroSense Therapeutics announced that Health Canada approved the commencement of patient enrollment in Canada for the Company's Phase 2b PARADIGM study of its combination therapy PrimeC for the treatment of amyotrophic lateral sclerosis, or ALS. Currently, over 50% of patients have been enrolled in PARADIGM with topline results expected in the second half of 2023. The FDA requested additional non-clinical data from NeuroSense to support the duration of the PARADIGM trial, as PrimeC is intended for long-term administration for the treatment of ALS. As a result, and following alignment with the agency on this subject, NeuroSense and the FDA have agreed that NeuroSense will withdraw its study protocol from the Investigational New Drug application, or IND. NeuroSense is planning a formal meeting with the FDA to align its clinical and regulatory strategy for a potential pivotal Phase 3 trial that is intended to support a New Drug Application (NDA) submission, pending the successful conclusion of the PARADIGM trial.

09:07 EST Muscle Maker crosses $200M milestone in first 3 months with new subsidiary - Muscle Maker announced its new wholly owned subsidiary, Sadot, has crossed the $200M revenue milestone in its first 3 months of operation. Sadot generated $58,517,750 in revenue in January 2023. Sadot, in its first three months of operation, has now generated $209,103,394 in total revenue for Muscle Maker. With over $200M in revenue in only 90 days, the Sadot diversification strategy and its management and guidance by AGGIA is proving to have a positive impact on Muscle Maker overall. AGGIA has performed and earned the right to nominate two additional board members to Muscle Maker upon exceeding $3.3 million in net income as per the performance metrics posted in the November 18, 2022 8K filing of the AGGIA service and operating agreements. "Our first undertaking for Sadot is focused on agricultural commodity shipping and trading," said Mike Roper, CEO of Muscle Maker, Inc. "We hired AGGIA to run the day-to-day operations of Sadot. AGGIA's experience and relationships in the agricultural industry have proven critical in the performance of Sadot to date. As part of our agreement with AGGIA and its key performance metrics, AGGIA earned the right to nominate 2 additional members to the Muscle Maker board of directors. Just last week, the company announced the addition of Hannah Oh and Ray Shankar to the Muscle Maker board of directors effective March 1, 2023. We are very excited to bring on key members with knowledge and experience in international and agricultural businesses."

09:06 EST Fat Brands accelerated organic growth in 2022 with 362 stores added to pipeline - FAT Brands announces it has experienced a historic year of growth, opening 142 new stores in 2022 and adding a total of 362 stores to its development pipeline which spans 29 states and 17 countries. Leading the way in new store development amongst FAT Brands' concepts was Fatburger and Buffalo's Express with 86 stores, Fazoli's with 61, Round Table Pizza with 56, and Twin Peaks with 50. Noteworthy franchise deals included a combined 80-store development agreement for 40 Fatburger and Buffalo's Express locations and 40 Round Table Pizza restaurants in the state of Texas, a 32-store agreement for Twin Peaks in Mexico, and a10-store agreement for Johnny Rockets in Israel. "We are extremely proud of our organic growth and the performance of our team in 2022," said Taylor Wiederhorn, Chief Development Officer of FAT Brands. "Franchisee interest was at an all-time high from both new and existing franchisees, which speaks volumes to our robust portfolio of brands that continue to deliver strong same-store sales and attract new fans around the globe. This year, we will remain focused on converting our over 1,000-unit pipeline into new stores, approximately 175 of which are set to open in 2023, along with continuing to fuel our long-term growth with additional development deals."

09:05 EST Hempacco, New to The Street sign 12-month media contract - New to The Street and Hempacco Co. signed a 12-month media contract to produce and air an informational series on New to The Street's syndicated and sponsored television networks. The contract calls for the New to the Street's news host to interview key corporate representatives from Hempacco Co., Inc. Then each interview will be broadcast across New to The Street's syndicated televised platforms on Newsmax TV and the FOX Business Network, and as a sponsored program on Bloomberg TV.

09:04 EST Couchbase names Fidelma Butler as Chief People Officer - Couchbase announced Fidelma Butler has joined the company as chief people officer. Butler will lead the people function, aligned with the company's values and operating objectives. Butler brings a wealth of experience and leadership to Couchbase, with a focus on scaling SaaS teams and building award-winning company culture. She comes to Couchbase from Zendesk and was most recently vice president of the talent and organizational development team.

09:04 EST Sharps Technology announces closing of $3.8M private placement - Sharps Technology closed its previously announced private placement pursuant to a securities purchase agreement with institutional investors on February 3, 2023. The aggregate gross proceeds of the private placement were approximately $3.8 million priced at the market under Nasdaq rules. Proceeds will help support the manufacturing of pre-filled specialty syringe systems through its partnership with Nephron Pharmaceuticals. In connection with the offering, the Company issued 2,248,521 units at a purchase price of $1.69 per unit priced at-the-market under Nasdaq rules. Each unit consists of one share of common stock and one non-tradable warrant exercisable for one share of common stock at a price of $1.56. The warrants have a term of five years from the issuance date. Gross proceeds were $3.8 million before deducting fees to the placement agent and other offering expenses payable by the Company. Aegis Capital Corp. acted as the Exclusive Placement Agent in connection with the offering.

09:03 EST GSE Systems awarded $800K contract - GSE Solutions announced it was awarded a new contract in partnership with a nuclear fuels, technology and services supplier to support a large US-based utility with new engineering program services supporting a 24-month fuel cycle operation project. The shift to 18- to 24-month fuel cycles results in fewer plant outages and provides utilities with improved fuel reliability and operating margin without adopting additional initiatives, such as higher burnup and enrichment levels. The project involves a tailored approach to achieving 24-month fuel cycles for a prominent nuclear generating station, where refueling is a critical step in maintaining operational efficiencies and major cost savings. This award is through a longtime, broad GSE partnership with the provider, valued at approximately $800K. The contract agreement includes GSE management of several complex engineering programs delivered directly to the nuclear power plant.

09:02 EST Galiano Gold reports double fatality at Asanko Gold Mine - Galiano Gold (GAU) deeply regrets to report that two contractors have been fatally injured yesterday following an incident at the Asanko Gold Mine located in Ghana, West Africa. The AGM is a 50:50 joint venture with Gold Fields (GFI), which is managed and operated by Galiano. AGM Emergency Services responded to the incident near the tailings storage facility where two contractors were pronounced deceased at the scene. The company is working alongside its contractor to ensure everyone impacted by the incident is provided the required support and counseling needed during this challenging and difficult time. "On behalf of Galiano Gold, we offer our sincerest condolences to the family, friends, and co-workers of our two colleagues," said Matt Badylak, President and CEO. The appropriate authorities have been notified and an investigation is underway. Efforts are immediately underway to further reinforce the sustained company commitment to Zero Harm and industry best practices in safety culture.

09:02 EST Fortinet announces FortiSP5 ASIC technology - Fortinet announced FortiSP5, the latest breakthrough in ASIC technology from Fortinet, propelling major leaps forward in securing distributed network edges. Building on over 20 years of ASIC investment and innovation from Fortinet, FortiSP5 delivers significant secure computing power advantages over traditional CPU and network ASICs, lower cost and power consumption, the ability to enable new secure infrastructure across branch, campus, 5G, edge compute, operational technologies, and more.

08:47 EST MSC Industrial receives proposal to exchange Class B shares for Class A shares - MSC Industrial Supply confirmed it has received a proposal from its controlling shareholders, the Jacobson/Gershwind family, to exchange its high-voting Class B shares, 10 votes per share, for Class A shares, 1 vote per share, and eliminate the current dual-class share structure. The Proposal is that each Class B share be exchanged for 1.35 Class A shares. The Proposal states that the family expects to remain MSC's largest shareholder, whether or not the proposed transaction occurs. The MSC Board of Directors has formed a Special Committee composed entirely of independent directors to evaluate the Proposal which will be advised by independent financial and legal advisors. Kirkland & Ellis has been retained as the legal advisor to the Special Committee. Under the terms of the Proposal, any definitive agreement would first require approval by the Special Committee and the MSC Board of Directors, as well as the holders of a majority of the Class A shares that do not also hold Class B shares.

08:40 EST American Resources reduces debt by over $9M - American Resources announces that its final convertible debt holder, Golden Properties Ltd. has elected to convert all of their Senior Convertible Debentures due March 31, 2023 to shares of class A common stock of the Company in a move that reduces the debt of the Company by over $9 million and eliminate the last of the Company's convertible debt. Golden Properties Ltd., an early shareholder and consistent supporter of the Company, will increase its long-term equity position in the Company's common stock through the conversion of the balance of its convertible debt, amounting to approximately $9.9 million, and resulting in approximately 9.4 million shares issued to the shareholder. Golden Properties was an original investor in American Resources Corporation and has increased its ownership steadily over time through additional investment.

08:36 EST ReShape Lifesciences announces pricing of upsized $10.2M public offering - ReShape Lifesciences announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. Each unit is being sold at a public offering price of $8.00. The warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance. Alternatively, each warrant will become exercisable for 0.75 shares of common stock under the cashless exercise provision included in the common warrants rather than the 1.5 shares of common stock under the cash exercise provision. The shares of common stock and accompanying warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $10.2 million. The company intends to use the net proceeds of this offering to continue implementation of its growth strategies, for working capital and general corporate purposes. The offering is expected to close on February 8, 2023, subject to customary closing conditions. ReShape has also granted the underwriters an option to purchase an additional 191,250 shares of common stock and/or additional warrants to purchase up to 286,875 shares of common stock, to cover over-allotments, if any. Maxim Group LLC is acting as sole book-running manager in connection with this offering.

08:35 EST Vision Sensing pays fee to extend period to consummate business combination - Vision Sensing Acquisition announced that on February 2, 2023, its sponsor, Vision Sensing, paid, and Continental Stock Transfer & Trust Company received a deposit in the Company's trust account in an aggregate of $1,012,000, representing the sum needing to be paid by Company to extend the date on which Company must consummate its initial business combination from February 3, 2023 to May 3, 2023. The Company has issued to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $1,012,000 as consideration for the funding.

08:35 EST Diebold announces Octavio Marquez was elected Chairman - Diebold Nixdorf announced that Octavio Marquez, president and CEO, was elected chair of the company's Board of Directors, effective February 2. Marquez was appointed as Diebold Nixdorf president and CEO on March 11, 2022. The Board determined that combining the roles of CEO, president and chairman under one leader enhances the alignment between ongoing strategic and operational matters, including focus on deleveraging and evaluating strategic opportunities to deliver value to shareholders. Independent director Arthur Anton, previously chair of the company's Finance Committee and former CEO of Swagelok, a global manufacturing company, was appointed as lead independent director of the Board. Gary Greenfield, who joined the Board in 2014 and has served as non-executive chairman since 2018, led the Diebold Nixdorf Board of Directors during a number of transformational developments, including the delivery of essential services and solutions to global financial institutions and retailers during the COVID-19 pandemic. He will not stand for re-election as a director at the company's annual shareholder meeting in 2023. The Board also appointed Marjorie L. Bowen and Emanuel "Manny" Pearlman as directors of the company effective immediately. The Board also anticipates reducing the overall size of the Board at the upcoming annual shareholders' meeting.

08:34 EST Cenntro Electric begins production of battery packs in United States and Germany - Cenntro Electric Group announced that it has begun to assemble and produce battery packs using lithium iron phosphate battery cells and Cenntro's proprietary battery management technologies. The battery packs are being assembled at Cenntro's Freehold, NJ facility and the Herne Plant in Germany. The resulting battery packs will offer longer cycle life and faster rates of charge, along with safer operations. The battery packs will initially be installed in Cenntro's Metro Series commercial vehicles. "By manufacturing our own battery packs, we hope to enhance supply chain efficiency, improve battery resilience, and ultimately have better control over one of the most strategic elements in our supply chain," said Peter Wang, Chairman, and CEO. "Our ability to support multiple battery assembly operations demonstrates our effort and commitment to promoting local sourcing and local production." The in-house assembly of the battery packs will initially utilize externally sourced battery cells. Cenntro will continue developing additional battery packs for its product line and, in the future, incorporate battery cells produced by its subsidiary Cennatic Power, Inc.

08:33 EST Align Technology announces $250M ASR, share purchase from executives - Align Technology announced that it has entered into a new accelerated stock repurchase agreement, or ASR, with Citibank, to repurchase $250M of Align's common stock under Align's $1B stock repurchase program announced on May 13, 2021. In addition to the ASR, Align announced that Joe Hogan, president and CEO, and John Morici, CFO and executive vice president, global finance intend to personally purchase $1M and $0.2M, respectively, of Align's common stock.

08:32 EST Verb begins implementation of plan to combat illegal short selling of shares - Verb Technology Company announces that it has recently engaged ShareIntel - Shareholder Intelligence Services, among other forensic professionals, and an investigation into potential illicit trading activity in its shares, and those responsible, is underway. ShareIntel's experienced team of professionals, leveraging their proprietary "Data Repository Information Link" technology, combine and analyze data from clearing firms, broker-dealers, reporting entities, and other sources to provide actionable intelligence. This analysis will help serve to direct the course of actions VERB's board may implement to protect the Company's shareholders. "While we intend to move swiftly, we will move thoughtfully, guided and driven by the data," states Rory Cutaia, VERB CEO. "In addition to possible enforcement actions, our board is currently considering shareholder focused initiatives, including the issuance of a special dividend. We are also paying close attention to the work other companies are doing to combat illicit trading activity, as we consider adopting those strategies and initiatives that appear to produce the most promising results. Among those strategies are Genius Group's issuance of an NFT to shareholders for Genius Group's services, an innovative initiative we applaud, and a version of which may be particularly interesting for our shareholders, for products available on our MARKET.live livestream social shopping platform."

08:27 EST Golar LNG to acquire New Fortress Energy's stake in FLNG Hilli - Golar LNG Limited (GLNG) has agreed to acquire the New Fortress Energy (NFE) ownership stake in FLNG Hilli in exchange for Golar's remaining 4.1M shares in NFE and $100M in cash. Golar will also take over approximately $323M in debt obligations linked to Hilli. Pursuant to the transaction, Golar will acquire the 50% interest in Trains 1 and 2 of FLNG Hilli, currently owned by a subsidiary of NFE. Following closing of the transaction, Golar's effective interest in currently contracted FLNG Hilli earnings will be as follows: 94.55% of Common Units that receive tolling related fees relating to trains 1 and 2, and 5% of Dutch Title Transfer Facility related fees, 89.1% of Series A units that receive Brent oil related fees, 89.1% of Series B units that receive 95% of TTF related fees. Following the transaction Golar will have no remaining shareholding in NFE. Subject to customary conditions, the transaction is expected to close in Q1 2023.

08:25 EST Forward Air to expand expedited LTL service offering in Chicagoland area - Forward Air s executing a growth strategy that involves organic infrastructure investments, including its ongoing less-than-truckload network expansion, as well as inorganic investments, such as the recently-signed acquisition of Land Air Express. Forward announced that it will expand its expedited LTL service offering in the Chicagoland area with a new terminal in Bolingbrook, IL, near Midway International Airport...Tom Schmitt, Chairman, President, and Chief Executive Officer said, "We continue to make investments that help our customers win more business. Our Bolingbrook facility is another example of how we do it. The combination of speed and the lowest damage rates in the industry is a differentiator for companies looking to grow."

08:24 EST AGF Management announces normal course issuer bid - AGF Management announced that the Toronto Stock Exchange has approved AGF's notice of intention to renew its normal course issuer bid in respect of its Class B Non-Voting Shares. As at January 26, 2023, there were 65,644,7721 Class B Non-Voting Shares issued and outstanding and the public float consisted of 43,979,233 Class B Non-Voting Shares. Under the announced normal course issuer bid, AGF is permitted to purchase up to 4,397,923 Class B Non-Voting Shares, representing approximately 10% of the public float for such shares as of January 26, 2023. Purchases under the normal course issuer bid may commence on February 8, 2023 and continue until February 7, 2024, when the bid expires. Pursuant to the Articles of AGF, the Class B Non-Voting Shares may not be purchased by AGF at a price which exceeds more than 15% of the weighted average price at which the Class B Shares traded on the TSX during the ten trading days immediately preceding the date of any such purchase. AGF announced that it will be entering into an automatic purchase plan with a broker during the normal course issuer bid. The Plan is effective as of February 8, 2023 and should terminate together with the normal course issuer bid. The Plan allows for purchases by AGF of its Class B Non-Voting Shares, subject to certain parameters. Under the announced normal course issuer bid, purchases may be made through the facilities of TSX, alternative Canadian trading systems /other published markets, or as otherwise permitted by the Canadian Securities Administrators or Ontario Securities Commission. The average daily trading volume of the Class B Non-Voting Shares on the TSX was 127,221. Under the rules of the TSX, AGF is entitled to repurchase during the same trading day on the TSX up to 25% of the ADTV of its Class B Non-Voting Shares, being 31,805 except where reliance is placed on the TSX's block purchase exemption. Class B Non-Voting Shares purchased under the NCIB will be canceled or purchased and held by the AGF Employee Benefit Trust for the settlement of equity settled incentive plans by AGF. The directors believe that the purchase for cancellation of Class B Non-Voting Shares represents a desirable use of capital when, if in the opinion of management, the value of the Class B Non-Voting shares is attractive relative to the trading price of said shares. Purchase for cancellation by AGF of outstanding Class B Non-Voting Shares may also be used to offset the dilutive effect of treasury stock released for the employee benefit trust and of shares issued through AGF's stock option plans and dividend reinvestment plan. Under its existing normal course issuer bid, which expires on February 7, 2023, AGF sought and received approval from the TSX to purchase 4,889,630 Class B Non-Voting Shares. During the period from February 8, 2022 to February 2, 2023, AGF acquired 2,460,123 Class B Non-Voting Shares at a weighted average price of $6.87.

08:22 EST Genetic Technologies to launch risk test for Breast & Ovarian cancer - Genetic Technologies provides further updates. The innovation and development of its Risk Test for Breast & Ovarian Cancer is inspired by direct response and feedback from the payer conversations such as insurance providers, employers, and healthcare providers. There is an unmet need to develop a unique single saliva risk assessment test that combines gene mutation for breast and ovarian cancers, hereditary and sporadic indicators and other relevant clinical risk factors. There is no other single test on the market that provides this array of information from a single test. The company has multiple patents granted1 and pending that support the combination of genetic and clinical risk factors. GTG is in discussions with a range of US payers regarding the adoption of the geneType breast cancer risk assessment test. While no commercial agreements are in place at this time, there are commercial pilot protocols in place with a few U.S. based payer groups. The Company's progress regarding the Company's endeavours in this regard have been previously referred to in the Company's ASX submitted quarterly updates and recent investor presentations. GTG have also engaged Alva10 to assist the Company with its U.S. payer engagement strategy.

08:21 EST Elbit Systems, ScoutCam complete development stage in RTVM program - ScoutCam and Elbit Systems completed a major development stage in the use of ScoutCam's real time video monitoring system. During the development stage, the RTVM system used on Elbit Systems' UAS platform acted as a replacement of manual pre and post flight visualization inspections of the aerial platform and provided clear visibility of areas that had previously been inaccessible to maintenance and operations teams. In addition, ScoutCam's RTVM provided visibility even when the operating ambience was not suitable for continuous real-time monitoring.

08:20 EST Mobilicom joins Association for Uncrewed Vehicle Systems International - Mobilicom announced it has become a member of the Association for Uncrewed Vehicle Systems International and the Fortress Information Security Trusted Cyber Program Cybersecurity Working Group which is developing enterprise cybersecurity standards to address cyber risks specific to uncrewed systems and robotics. Mobilicom joins as a contributing member of the group comprised of leading defense, drone, and cybersecurity companies including Boeing, Boston Dynamics, Northrup Grumman, and Raytheon.

08:18 EST LumiraDx receives FDA EUA, U.K. CTDA approval for LumiraDx SARS-CoV-2 assay - LumiraDx announced that it has received an Emergency Use Authorization, EUA, from the U.S. Food and Drug Administration and validation for use by the UKHSA under the CTDA process for the LumiraDx SARS-CoV-2 & Flu A/B STAR Complete assay that will allow high complexity laboratories to quickly identify and differentiate individuals suspected by a healthcare provider of respiratory viral infection consistent with COVID. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. This makes it essential to correctly identify them in order to treat and manage patients accordingly. The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete multiplex test allows for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2 infections within 20 minutes or less. "With the limited number of direct amplification multi-analyte tests available, we believe that this test will become a fundamental tool for the detection and differentiation of SARS-CoV-2 from influenza," explains Sanjay Malkani, President of the LumiraDx Molecular Diagnostics Business. "As the burden of respiratory illness continues, we look forward to providing our clinical diagnostic lab and reference lab customers with a high-throughput, highly sensitive multiplex test with results available in 20 minutes - and the added benefit of accurately detecting influenza and COVID from a single sample."

08:17 EST Zebra renews location solutions provider partnership with NFL through 2025 - Zebra Technologies announced the renewal of its partnership with the National Football League, extending Zebra's role as the Official Real Time Location Solutions Provider of the NFL through at least the 2025 football season. More details of the partnership will be discussed during the Zebra Super Bowl press conference on Wed., Feb. 8 at 3:30pm MT in Room 301C of the Super Bowl LVII Media Center in the Phoenix Convention Center in Phoenix, Arizona.... "We are excited to extend our relationship with Zebra Technologies, allowing us to utilize their best-in-class capabilities to capture data which enable next generation data insights and expanded visibility into every NFL game," said Matt Swensson, Senior Vice President, Product and Technology, National Football League. "Together, we are continuing to advance the League's commitment to innovation and improving all facets of our sport while providing our fans incredible insight into the game they love."

08:16 EST Revive Therapeutics secures MDMA supply from PharmAla Biotech - Revive Therapeutics (RVVTF) has entered into a supply agreement with PharmAla Biotech Holdings to obtain PharmAla's LaNeo, GMP source of 3,4-Methylenedioxymethamphetamine, for the development of Revive's microneedle patch delivery system. Recently, Revive Therapeutics announced it entered into a research collaboration agreement with PharmaTher Holdings (PHRRF) to evaluate their microneedle patch technology with MDMA.

08:14 EST ON Semiconductor announces $3B share repurchase authorization - The company also announced that its board of directors has approved a new share repurchase program with authorization to repurchase up to $3B of shares of the company's common stock through December 31, 2025.

08:13 EST NewAmsterdam appoints John Smither to board of directors - NewAmsterdam Pharma (NAMS) announced the appointment of John Smither as an independent director to its Board of Directors. Smither will also serve as chair of NewAmsterdam Pharma's Audit Committee. Most recently, Smither served as the Chief Financial Officer at Arcutis Biotherapeutics (ARQT), where he was responsible for all financial aspects of the company's business, including leading Arcutis' successful initial public offering and two capital raises.

08:11 EST aTyr Pharma announces achievement of milestone by partner Kyorin Pharmaceutical - aTyr Pharma announced that its partner Kyorin Pharmaceutical has dosed the first patient in Japan in EFZO-FIT, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company's lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, ILD. This achievement has triggered a $10M milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin. "We are very pleased with Kyorin's timely start to EFZO-FIT and are happy to have centers open for enrollment in Japan, which is an important part of this large, global study," said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Kyorin is responsible for the clinical development of efzofitimod for ILD in Japan and is an essential partner for aTyr as we work to bring this transformative, disease modifying therapy to sarcoidosis patients."

08:10 EST Astrotech appoints Thomas Pickens III to serve as CTO - Astrotech Corporation announced that its Board of Directors has appointed Thomas Pickens III to serve as its Chief Technology Officer, CTO, in conjunction with his current duties as Chief Executive Officer. Tom Wilkinson, Astrotech's lead independent director said, "The appointment of Tom Pickens as CTO more accurately reflects the dual roles he has been managing since the consolidation of our operations in Austin, Texas. He has consistently demonstrated his proficiency in identifying new applications for our Astrotech Mass Spectrometer Technology and is key in the design of innovative sample collection and quantitation techniques."

08:09 EST Israel Railways purchases 10 Rail Vision Main Line Systems for $1.4M - Rail Vision announced that Israel Railways Ltd., Israel's state-owned principal railway company, signed an agreement to purchase 10 Rail Vision Main Line Systems and related services for $1.4M.

08:08 EST Amarin mails letter to shareholders highlighting Sarissa's myths vs facts - Amarin Corporation announced that it has mailed a letter to shareholders addressing the false and misleading statements made by Sarissa Capital Management and filed an investor presentation with the U.S. Securities and Exchange Commission urging shareholders to vote "AGAINST" all proposals on the WHITE proxy card. "Dear Shareholder, As we approach the February 28, 2023, General Meeting, you have an important decision to make regarding the future of your investment, and we want to ensure you have the facts. The bottom line is this: We understand your frustration and the stock price is not where we want it to be either. We agree that change was needed at Amarin - with a NEW Board, NEW management team and NEW strategy, we are working hard to turn Amarin around to drive value for you, our shareholders. In contrast, Sarissa is attempting to oust our new Chairman and de facto gain control of the Board with seven underqualified individuals by distorting the facts and in some cases, promoting outright misinformation. While Sarissa's 110-page presentation certainly taps into shareholder frustration, it conveniently ignores important facts that are critical to Amarin's fate... SARISSA MYTH #1...on Sarissa's ability to create value in the healthcare space. Despite Sarissa's suggestions to the contrary, appointing Sarissa nominees has been value destructive for the vast majority of companies that have done so... SARISSA MYTH #2...on M&A. The Board is committed to evaluating any real M&A opportunity that would maximize value for Amarin shareholders, including a sale of the Company... SARISSA MYTH #3...on comparing Amarin to The Medicines Company. Sarissa continues to compare Amarin to The Medicines Company, leading you to believe the same playbook will work here. The reality is the situation could not be more different. SARISSA MYTH #4...on European launch and reimbursement in Germany. Sarissa has no understanding of the German market and very limited experience with international operations. SARISSA MYTH #5...on a subscription model. Sarissa is recycling ideas about subscription models already considered and rejected by the Amarin Board for good cause. SARISSA MYTH #6 ...on cost savings. Within two months of taking over as CEO, in August 2021, Karim Mikhail took swift and decisive action to reduce the salesforce by 50%. SARISSA MYTH #7 ...on Per Wold-Olsen and Karim Mikhail's purported working relationship at Merck. Implying that Chairman Per Wold-Olsen and CEO Karim Mikhail had a close working relationship at Merck is false. SARISSA MYTH #8 ...on General Meeting timeline. Amarin set the meeting date as late as possible under UK law to provide shareholders the longest possible amount of time to vote. SARISSA MYTH #9 ...on Board refreshment. Amarin has conducted a comprehensive, independent and transparent refreshment process. SARISSA MYTH #10 ...on shareholder communications. We are a new Board that is working to create value for each and every one of you, and expanding our commitment to engagement is a part of that. We know we can do even more, and we will.

08:05 EST Volaris reports January ASMs up 16.0% from last year - Controladora Vuela Compania de Aviacion reports its January 2023 preliminary traffic results. In January, Volaris' capacity, measured in ASMs, increased by 16.0% year-over-year, while demand, measured in RPMs, increased by 23.1%; the result was a load factor expansion of 5.0 pp YoY to 86.2%. Volaris transported 2.9 million passengers during the month, a 21.8% increase compared to January 2022. Demand in the domestic Mexican and international markets increased by 17.9% and 35.7%, respectively.

08:04 EST Reed's appoints Chris Burleson as CCO - Reed's announces the appointment of Christopher Burleson as Chief Commercial Officer. As Chief Commercial Officer, Burleson will lead the sales organization as well as partner with the operations department to streamline supply chain and cost reductions initiatives. He will also focus on strategic partnerships and growth opportunities leveraging his financial experience enhancing profit targets.. Burleson was formerly the Vice President of Sales, US-Retail at Fever-Tree Drinks.

08:03 EST Oxford Lane estimates NAV per share $5.02-$5.12 as of January 31 - Management's unaudited estimate of the range of the NAV per share of our common stock as of January 31, 2023 is between $5.02 and $5.12. This estimate is not a comprehensive statement of our financial condition or results for the month ended January 31, 2023. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending March 31, 2023 may differ materially from this estimate, which is given only as of January 31, 2023. As of January 31, 2023, the Company had approximately 167.4 million shares of common stock issued and outstanding.

08:02 EST Seelos Therapeutics doses first patients in ethnobridging study with SLS-002 - Seelos Therapeutics announced that it has dosed the first patients in an ethnobridging study in healthy adult Japanese and non-Asian subjects to compare the safety and pharmacokinetic profiles of SLS-002. Seelos consulted and received endorsement from the Pharmaceuticals and Medical Devices Agency in Japan and from the U.S. FDA to conduct this Phase I ethnobridging study. Study SLS-002-103 will measure elements such as dosage and administration, sample size, inclusion and exclusion criteria, endpoints, and blood sampling. Seelos expects that data from this study will help inform inclusion of Japanese subjects in the design of a future global trial in patients with major depressive disorder at imminent risk of suicide.

07:57 EST Lyra Therapeutics completes enrollment in BEACON Phase 2 trial of LYR-220 - Lyra Therapeutics announced completion of enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have had prior sinus surgery. LYR-220 is designed to deliver six months of continuous anti-inflammatory medication to the sinonasal passages for the treatment of CRS. Topline results are expected in the fourth quarter of 2023. The Phase 2 BEACON trial is a sham-controlled, parallel-group study to evaluate safety and efficacy of the LYR-220 matrix, over a 24-week period, in symptomatic adult CRS patients who have had a prior bilateral ethmoid sinus surgery. The trial consists of two parts: Part 1 was designed primarily to assess the feasibility and tolerability of two 7500microgram MF matrix designs; in Part 2, 40 patients have been randomized 1:1 to receive LYR-220 or sham control.

07:40 EST Clearside Biomedical announces leadership update - Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ciulla will chair the Company's Scientific Advisory Board, SAB, sharing his medical expertise as a practicing retinal specialist and providing counsel on Clearside's ODYSSEY Phase 2b clinical trial and other suprachoroidal development programs.

07:39 EST Textron subsidiary receives order from OEM - Kautex Textron, a Textron company, announced it has received the first order from an automotive OEM for a thermoplastic composite underbody battery protection skid plate. The skid plate is part of the company's new Pentatonic battery system product line supporting battery electric vehicle production.

07:37 EST PyroGenesis provides update on recent contract to supply SPARC in New Zealand - PyroGenesis Canada announces that, further to its Client's Press Release dated February 4, 2023, and PyroGenesis' Press Releases dated January 10, 2023 and September 13, 2022, the Company can now provide important additional information on its recently signed contract for the purchase of its SPARC refrigerant waste destruction system by its Client in New Zealand. The Company's SPARC system has been purchased as the core technology for New Zealand's national hazardous refrigerant collection and destruction initiative, the government-mandated organization known as Cool-Safe. Cool-Safe's mandate is to be a significant factor in the government of New Zealand's stated goal to reduce their greenhouse gas emissions by 2035 by at least 35%. This will be achieved by implementing their own 90% reduction target for hazardous refrigerants. "When we originally announced this contract, we were limited in what we could reveal. Given their latest press release we can now confirm that our Client is a very large, government-mandated organization serving the whole of New Zealand, and is comprised of not just one, but nine advanced materials/chemical trading companies working together," said P. Peter Pascali, CEO and Chair of PyroGenesis. "As with most Product Stewardship Organizations, these companies have been given the responsibility to oversee, in this case, the safe removal and disposal of the hazardous products they either manufacture or distribute. The nine companies within the Cool-Safe organization are significant players in their own right and include four that are large publicly traded multi-nationals and six that are 50+ years old."

07:35 EST Vitalhub enters multiyear licensing with Habitat Services - VitalHub announced the licensing of the Company's proprietary TREAT Client Information System to Habitat Services. Habitat Services is a Toronto-based non-profit housing agency and that has been utilizing VitalHub's Pirouette case management software for many years. They are one of 50 service providers within the Toronto Mental Health and Addictions Access Point network.Habitat is investing to improve, enhance, and modernize the support of their workflows by migrating to the comprehensive TREAT client information system to better suit the needs of their employees and the services they provide. Habitat Services has signed a five-year agreement with VitalHub to license the TREAT software with the goal of this being the long term solution for their client referrals, supports, and housing subsidy administration.

07:34 EST Saia announces new revolving credit facility - Saia announced that it has closed on a new unsecured revolving credit facility with committed borrowing capacity of $300 million and an incremental $150 million accordion feature. This credit facility replaces the Company's existing secured $300 million revolving credit facility, which was scheduled to mature in February 2024. On February 3, 2023, the Company entered into a credit agreement with JPMorgan Chase Bank, N.A. as Administrative agent, BOKF, NA as Syndication Agent, and Bank of America, PNC Bank, National Association and TD Bank, N.A., as Co-Documentation Agents. Among other items, the new credit facility: Allows Saia to access capital without pledging collateral; Maintains the size of the credit facility commitments of $300 million; Increases the availability under an accordion feature from $100 million to $150 million; Extends the maturity until February 3, 2028; Provides an interest rate pricing grid with more favorable borrowing costs.

07:32 EST React Gaming announces 2023 growth strategy for Compete.gg - React Gaming Group announced Compete.gg's growth strategy for 2023 and beyond. One key aspect of AI/ML tech is that it can drive revenue for Compete.gg via predictive analytics. By analyzing user data and behaviour, the platform can provide insights and recommendations to users about tournaments, players, and other features that are most relevant to their interests. This not only creates a more enjoyable experience for users but also increases the likelihood that they will participate in more tournaments and engage more deeply with Compete's platform. Another way that AI/ML can drive revenue for Compete is through targeted advertising. By using machine learning algorithms to understand user behaviour and interests, the platform can serve more relevant and effective advertisements to users, leading to increased click-through and higher conversion rates. It also allows the platform to better pair advertisers with the right tournament organizers and brands. Additionally, and probably most importantly, by leveraging AI and ML, Compete can optimize its tournament creation and management processes, making it easier and more efficient for tournament organizers to run tournaments and manage their communities. This can help reduce administrative overhead and increase the number of tournaments offered on our platform, further increasing user engagement and driving revenue. The integration of AI and ML into a Compete mobile offering can significantly increase the company's revenue in the next two years by providing users with a more personalized and engaging experience, increasing the effectiveness of targeted advertising, and streamlining tournament management processes, all via the one device everyone has in their pocket, a smartphone. The good news is that Compete's platform is built to be adaptable to mobile functionalities, but it will take some time to become fully operational.

07:31 EST Context Therapeutics highlights clinical responses from Phase 2 OATH trial - Context Therapeutics announced that two patients have achieved a confirmed partial response, PR, among the first 12 patients enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context's oral progesterone receptor antagonist onapristone extended release, ONA-XR, in combination with anastrozole, ANA, to treat hormone receptor positive metastatic endometrial cancer. "Data from the ongoing Phase 2 OATH clinical trial supports the potential for ONA-XR plus ANA combination therapy to serve as an effective therapeutic option in metastatic EC. We are encouraged by these findings and look forward to continued enrollment in the trial," said Martin Lehr, CEO of Context Therapeutics. Preliminary data from the ongoing Phase 2 OATH clinical trial evaluating the combination of ONA-XR with ANA in HR+ EC found that ONA-XR plus ANA demonstrated a 4-month progression free survival rate of 77% and an overall response rate of 22%. These results suggest that ONA-XR plus ANA exhibits favorable efficacy and tolerability relative to historical data that evaluated physician's choice of chemotherapy versus Lenvima plus Keytruda combination therapy in a similar treatment setting of metastatic EC.

07:14 EST NeoGenomics announces results from study of RaDaR assay - NeoGenomics announced results of a new study of the RaDaR assay in patients with muscle-invasive bladder cancer immediately following treatment with a combination of the immune checkpoint inhibitors in the neoadjuvant setting. Plasma and urine collected from the patients during treatment was analyzed. The RaDaR assay is a personalized, highly-sensitive sequencing test for the detection of minimal residual disease and recurrence. MRD is the trace amounts of circulating tumor DNA that remain after surgery or other cancer treatment. The study, published in the journal Nature Medicine, found that the absence of ctDNA in plasma - as detected by RaDaR - was associated with patient responses to treatment prior to surgery offering the possibility of avoiding aggressive surgery that removes the patient's bladder. The new data are part of the second cohort of the Phase 1b/2a NABUCCO trial, which investigated patient responses to neoadjuvant treatment with a CTLA-4 inhibitor in combination with a PDL1 inhibitor among patients with locoregionally-advanced urothelial cancer. In both cohorts, RaDaR assay was used before and during neoadjuvant therapy as well as pre-surgery to assessed ctDNA in urine and blood plasma to determine patient response to treatment. Cohort 1 helped establish the feasibility of neoadjuvant therapy with ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, demonstrating high pCR rates. In Cohort 2, patients received either ipilimumab 3 mg/kg plus nivolumab 1 mg/kg or ipilimumab 1 mg/kg plus nivolumab 3 mg/kg, both for two cycles, followed by nivolumab 3 mg/kg. Overall, 43 percent in cohort 2A and 7 percent in cohort 2B achieved a complete pathological response, the primary endpoint. The absence of ctDNA in blood plasma was highly associated with both pCR and PFS. In urine, the absence of ctDNA was linked to pCR but not PFS.

07:13 EST View Inc. unveils new Smart Windows installation at Chicago's ORD - View unveiled its new extensive Smart Windows installation this week at the recently completed 350,000-square-foot expansion of Terminal 5 at Chicago's O'Hare International Airport, ORD. The Terminal 5 expansion includes several new gates and two new lounges with View Smart Windows. "This project sets the standard for sustainable, passenger-centric airport design," said Dr. Piers MacNaughton, VP of Institutional Business at View Inc. "We are proud to contribute to O'Hare's sustainability initiatives and make a good first impression of Chicago for the millions of passengers that travel through Terminal 5 each year."

07:11 EST Freshworks, Meta partner to help conversational customer experience - Freshworks (FRSH) announced that companies around the world have increased customer retention by using Freshworks' conversational AI bots to automate communication with buyers through WhatsApp, Instagram Messaging, and Facebook Messenger (META). International companies like MTN Cameroon in Africa, Body & Fit in Europe and The Giving Movement in Dubai have elevated their customer support efficiency on Meta's messaging platforms using Freshworks' Freshchat, Freshdesk and Freshsales products. With over two billion daily active WhatsApp users, nearly two billion daily active Facebook users, and more than two billion monthly active Instagram users, Meta provides the world's most popular messaging platforms. The Meta Business Messaging integrations with Freshworks' CX and CRM products make customer and prospect engagement easy for support, sales, and marketing teams.

07:09 EST Carlyle Group names Harvey Schwartz as CEO, board member - Global investment firm Carlyle (CS) announced that its Board of Directors has unanimously agreed to appoint Harvey M. Schwartz as Chief Executive Officer and a member of the Board, effective February 15, 2023. At that time, Bill Conway will step down as Interim CEO, maintaining his role as Co-Chairman of the Board. Schwartz is the former President and Co-Chief Operating Officer of The Goldman Sachs Group (GS), and prior to that, served as the firm's Chief Financial Officer, where he oversaw its most critical financial and risk management processes as well as its capital allocation strategy. He also held leadership roles across a broad range of the firm's operations, including its Securities and Investment Banking divisions, where he was instrumental in driving the growth of a number of the firm's client franchises. At Carlyle, Schwartz will be responsible for setting and executing a strategy that advances and accelerates the diversification plan the firm has successfully pursued, as well as identifying new investment opportunities to further grow and scale the firm, drive sustained performance for fund investors, and create significant shareholder value.

07:08 EST BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 20 newly-hired employees stock options to purchase an aggregate of 287,200 shares, and restricted stock units covering an aggregate of 101,700 shares, of BioCryst common stock. The options and RSUs were granted as of January 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.55 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

07:07 EST Singular Genomics announces launch of Max Read Kits - Singular Genomics Systems announced the launch of its Max Read Kits for single cell applications on the company's G4 Sequencing Platform at the Advances in Genome Biology and Technology, AGBT, 23rd General Meeting, taking place February 6-9, 2023, in Hollywood, Florida. The Max Read Kits boost the potential output of the G4 to a market-leading 3.2 billion reads per run on a benchtop system for single cell sequencing. The kits, specifically designed to match the format of popular 10x Genomics assays, enable users the flexibility to sequence 4, 8, 12, or 16 samples per run, each in its own lane. "We believe the combination of speed, flexibility, cost, and power that the Max Read Kits provide will firmly establish the G4 as the leading benchtop system for customers running single cell applications," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We look forward to sharing data at AGBT and to begin shipping to our customers in the second quarter of this year... We have seen consistent improvement on the throughput of our flow cells and, for certain applications, we are now achieving up to 1.8 billion reads per run on the F3 flow cells. We've been especially pleased with the quality of data coming from our F3 flow cells and are excited to start sending these to select customers later this month," added Spaventa.

07:04 EST Tonix Pharmaceuticals initiates enrollment in Phase 2 'PREVENTION' study - Tonix Pharmaceuticals Holding announced that the first participant was enrolled in the Phase 2 'PREVENTION' study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. The double-blind, placebo-controlled study has a target enrollment of 300 participants at approximately 25 sites across the U.S. Results from a planned interim analysis are expected to be released in the fourth quarter of 2023.

07:03 EST Lava Therapeutics appoints Charles Morris as CMO - LAVA Therapeutics (LVTX) announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. Most recently, Morris was the chief medical officer for Celyad Oncology (CYAD).

07:02 EST Aterian announces management promotions, changes - Aterian announced it has made several management promotions and changes that the Company believes will further streamline its operations as it continues to target Adjusted EBITDA profitability in the second half of 2023. Mihal Chaouat-Fix has been promoted to Chief Supply Chain Officer. Chaouat-Fix joined the Company in 2014 and has served as Aterian's Chief Product Officer since September 2018. Tim Stanton has been promoted to Chief E-Commerce Officer. Stanton joined Aterian in September 2017, most recently serving as Aterian's Senior Vice President of E-commerce. Phil Lepper has been promoted to Senior Vice President of Revenue and is responsible for brand strategy and management of Aterian's portfolio of brands. Lepper joined Aterian in June of 2021 and most recently served as the Company's Vice President of Revenue for hOmeLabs and Vremi Brands. As part of these changes, the Company also announced that it has eliminated the position of Chief Operating Officer. Anton von Rueden, who served in that position, will continue to assist the Company with the transition of responsibilities during the next few months.

06:57 EST Tyson Foods sees FY23 CapEx $2.5B

06:54 EST Novartis' Sandoz BLA for proposed biosimilar denosumab accepted by FDA - Sandoz announced that the U.S. Food and Drug Administration has accepted its Biologics License Application, or BLA, for proposed biosimilar denosumab. "In addition to being an important medicine for cancer of the bone, denosumab is critical in the treatment of osteoporosis and potential prevention of osteoporosis-related fractures that so many women over 50 are at risk of. We are proud to be among the first to submit a BLA for a denosumab biosimilar as, if approved, it could increase patient access to an affordable, high-quality, potentially disease-modifying treatment across the US, while also delivering savings for healthcare systems," said Keren Haruvi, President, Sandoz Inc. and Head of North America.

06:48 EST Southwest Dispatchers and Facilities Maintenance Technicians approve CBAs - Southwest announced its Dispatchers and Facilities Maintenance Technicians have voted in favor of their new collective bargaining agreements, or CBAs. Southwest's Dispatch Employees, represented by the Transport Workers Union Local 550, or TWU 550, have voted in favor of their new contract. This agreement covers Southwest's more than 450 Flight Dispatchers, Assistant Dispatchers, Flight Superintendents, Dispatch Specialists, and Dispatch ATC Specialists and becomes amendable June 1, 2027. This agreement covers Southwest's more than 450 Flight Dispatchers, Assistant Dispatchers, Flight Superintendents, Dispatch Specialists, and Dispatch ATC Specialists and becomes amendable June 1, 2027. Southwest's 50 Facilities Maintenance Technicians maintain, modify, and repair all facilities across its system to provide attractive and functional spaces for Customers and Employees alike. This agreement becomes amendable November 16, 2027. Since October 2022, five of Southwest's union-represented workgroups have voted in favor of new collective bargaining agreements-the Appearance Technicians, Customer Service Employees, Flight Instructors, Facilities Maintenance Technicians, and Dispatch Employees.

06:32 EST Biogen, Sage Therapeutics: FDA accepts NDA for zuranolone - Biogen (BIIB) and Sage Therapeutics (SAGE) announced the U.S. FDA has accepted the filing of a New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority review and the FDA has assigned a Prescription Drug User Fee Act action date of August 5, 2023.

06:18 EST Dell Technologies to reduce workforce by 5% - In a regulatory filing, Dell said that it announced to its employees reorganizations and actions to align its investments more closely with its previously discussed strategic and customer priorities. These actions will result in a reduction of approximately 5% of the company's workforce as the company continues to take prudent steps in light of a challenging global economic environment. The company expects to recognize expenses associated with these actions in the fourth fiscal quarter of fiscal 2023.

06:03 EST Acutus Medical reports results from AcQForce Flutter Study - Acutus Medical announced results from the AcQForce Flutter Study "AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter". Results were presented during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. "We are encouraged by the positive results of the AcQForce Flutter Study and our ability to help physicians deliver more efficient ablation therapy," said David Roman, President & CEO of Acutus Medical. "The study is a critical component of our PMA submission to expand our portfolio in the United States to include a fully integrated mapping and therapy solution, and these data reinforce our conviction that AcQBlate will be an important driver of our growth plans in 2023 and over the long-term." AcQForce Flutter Study enrolled 110 patients at 21 sites globally and was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter. Acute success was achieved in 94% of patients and there were no serious adverse events. Ablation time was 13.5 +/- 10.0 minutes, 33% less than comparative systems (20.0 +/- 14.0 min in BLOCK-CTI). AcQBlate required only 250.4 +/- 172.2 ml of irrigation during the procedure, significantly less than comparative systems (699 +/- 386 min in BLOCK-CTI). Overall, the study demonstrated comparable outcomes to historic controls with significantly shorter ablation time and lower fluid volumes. Acutus submitted its premarket approval application for the AcQBlate FORCE sensing ablation catheter and system on October 3, 2022 and is currently under review.

05:30 EST Newmont submits proposal to acquire Newcrest Mining - Newmont confirmed it has submitted a non-binding proposal to acquire 100% of the issued share capital of Newcrest Mining by way of a scheme of arrangement. The proposed transaction would combine two of the sector's senior gold producers. Newmont's proposal to combine with Newcrest is on the basis of 0.380 Newmont shares per Newcrest share, which would result in the combined company being 30% owned by Newcrest and 70% owned by Newmont. Newmont's proposal is subject to certain customary conditions, including due diligence to the satisfaction of both parties, entry into a scheme implementation agreement and a recommendation from the Newcrest board of directors that Newcrest shareholders vote in favor of the proposal.

05:15 EST Addex Therapeutics completes enrollment in part one of ADX71149 trial - Addex Therapeutics (ADXN) announced that enrollment into Part 1 of the Phase 2 clinical study of ADX71149 for the treatment of epilepsy has been completed. ADX71149 is a selective metabotropic glutamate type 2, or mGlu2, receptor positive allosteric modulator, or PAM. The trial is being conducted by Janssen Pharmaceuticals, part of Johnson & Johnson (JNJ). Data from Part 1 will now be evaluated by an independent interim review committee, or IRC, to ensure the study remains blinded. Based on the outcome of this review and recommendations from the IRC, Janssen will evaluate next steps for the program.